MCID: SFT003
MIFTS: 56

Soft Tissue Sarcoma

Categories: Rare diseases

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 52 58 29 42 17
Non-Rhabdomyosarcoma Soft Tissue Sarcoma 52
Malignant Mesenchymal Tumor 58
Malignant Soft Tissue Tumor 58
Connective Tissue Sarcoma 52
Sarcoma, Soft Tissue 39
Soft Part Sarcoma 58
Sarcoma 71

Characteristics:

Orphanet epidemiological data:

58
soft tissue sarcoma
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

UMLS via Orphanet 72 C0334492 C1261473
Orphanet 58 ORPHA3394
UMLS 71 C1261473

Summaries for Soft Tissue Sarcoma

NIH Rare Diseases : 52 Soft tissue sarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels , nerves, tendons and the lining of joints. Many people with early soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome , Gardner syndrome , Li-Fraumeni syndrome , Tuberous sclerosis , neurofibromatosis type 1 , and Werner syndrome ) have an increased risk of developing a soft tissue sarcoma. The best treatment options depend on many factors but may include surgery, chemotherapy , and radiation therapy .

MalaCards based summary : Soft Tissue Sarcoma, also known as non-rhabdomyosarcoma soft tissue sarcoma, is related to myxoid liposarcoma and sarcoma, synovial. An important gene associated with Soft Tissue Sarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lopinavir and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are cardiovascular system and endocrine/exocrine gland

MedlinePlus : 42 Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. NIH: National Cancer Institute

Wikipedia : 74 A soft-tissue sarcoma (STS) is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 690)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 33.0 TP53 MDM2 EWSR1
2 sarcoma, synovial 32.8 MDM2 FOXO1 EWSR1 BCL2
3 rhabdomyosarcoma 2 32.5 TP53 MDM2 FOXO1 EWSR1
4 li-fraumeni syndrome 32.2 TP53 MDM2 EGFR BCL2
5 liposarcoma 32.0 TP53 MDM2 EWSR1
6 muscle cancer 31.9 TP53 MDM2 FOXO1 EWSR1
7 histiocytoma 31.9 TP53 MDM2 EWSR1
8 leiomyosarcoma 31.7 VEGFA TP53 MDM2
9 retroperitoneal sarcoma 31.5 MDM2 EWSR1
10 dedifferentiated liposarcoma 31.3 TP53 MDM2
11 embryonal sarcoma 31.3 TP53 MKI67 MDM2
12 angiosarcoma 31.2 VEGFA TP53 MDM2
13 malignant peripheral nerve sheath tumor 31.0 TP53 MDM2 EGFR
14 embryonal rhabdomyosarcoma 31.0 TP53 MDM2 FOXO1 EWSR1
15 connective tissue disease 31.0 VEGFA TNF IFNG EWSR1
16 gastrointestinal stromal tumor 30.9 VEGFA TP53 MKI67 EGFR ABCB1
17 cellular myxoid liposarcoma 30.9 MDM2 EWSR1
18 rhabdomyosarcoma 30.8 VEGFA TP53 MDM2 FOXO1 EWSR1 EGFR
19 sarcoma 30.7 VEGFA TP53 MDM2 FOXO1 EWSR1 ABCB1
20 granulocytopenia 30.7 TNF CSF3
21 osteogenic sarcoma 30.6 TP53 TNF MDM2 ABCB1
22 stomatitis 30.6 TNF IFNG CSF3
23 fasciitis 30.5 TP53 TNF IFNG
24 doxorubicin induced cardiomyopathy 30.5 EGFR CSF3
25 bone osteosarcoma 30.4 TP53 MDM2 EWSR1
26 lymphangiosarcoma 30.2 VEGFA TNF
27 ring chromosome 30.2 TP53 MDM2 EWSR1
28 mucositis 30.2 VEGFA CSF3 ABCB1
29 cystitis 30.1 VEGFA TP53 TNF
30 toxic shock syndrome 30.1 TNF IFNG EGFR
31 b-cell lymphoma 30.0 TP53 MKI67 MDM2 BCL2
32 suppressor of tumorigenicity 3 30.0 TP53 BCL2
33 chordoma 29.9 VEGFA TP53 EGFR
34 exanthem 29.9 VEGFA TNF EGFR CSF3
35 inflammatory myofibroblastic tumor 29.9 TP53 MKI67 MDM2 BCL2
36 bone cancer 29.9 TP53 EWSR1 EGFR
37 peripheral nervous system disease 29.8 VEGFA TNF IFNG CSF3
38 osteonecrosis 29.7 VEGFA TNF ABCB1
39 neurofibroma 29.7 VEGFA TP53 EGFR
40 acquired immunodeficiency syndrome 29.7 TP53 TNF IFNG
41 appendicitis 29.7 TNF IFNG CSF3
42 acute graft versus host disease 29.6 TNF IFNG CSF3
43 osteomyelitis 29.6 TNF IFNG CSF3
44 aspergillosis 29.6 TNF IFNG CSF3
45 peritonitis 29.5 TNF IFNG CSF3
46 ewing sarcoma 29.5 VEGFA TP53 MDM2 FOXO1 EWSR1 EGFR
47 malignant glioma 29.5 VEGFA TP53 MDM2 EGFR
48 burkitt lymphoma 29.4 TP53 TNF CSF3 BCL2
49 brain edema 29.4 VEGFA IFNG CSF3
50 diffuse large b-cell lymphoma 29.3 VEGFA TP53 TNF MDM2 CSF3

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
2 endocrine/exocrine gland MP:0005379 10.26 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
3 growth/size/body region MP:0005378 10.25 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
4 cellular MP:0005384 10.24 BCL2 EGFR FOXO1 IFNG LATS1 MDM2
5 hematopoietic system MP:0005397 10.24 ABCB1 BCL2 CSF3 EGFR FOXO1 IFNG
6 digestive/alimentary MP:0005381 10.23 ABCB1 BCL2 EGFR FOXO1 IFNG MDM2
7 homeostasis/metabolism MP:0005376 10.22 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
8 immune system MP:0005387 10.21 ABCB1 BCL2 CSF3 EGFR FOXO1 IFNG
9 craniofacial MP:0005382 10.19 BCL2 EGFR FOXO1 IFNG MDM2 TNF
10 integument MP:0010771 10.19 BCL2 CSF3 EGFR FOXO1 IFNG LATS1
11 embryo MP:0005380 10.17 BCL2 EGFR FOXO1 IFNG MDM2 TNF
12 mortality/aging MP:0010768 10.13 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
13 liver/biliary system MP:0005370 10.11 ABCB1 EGFR FOXO1 IFNG LATS1 MDM2
14 neoplasm MP:0002006 10.02 BCL2 EGFR FOXO1 IFNG LATS1 MDM2
15 nervous system MP:0003631 10.02 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
16 muscle MP:0005369 10.01 BCL2 EGFR FOXO1 IFNG MDM2 TNF
17 no phenotypic analysis MP:0003012 9.96 ABCB1 EGFR FOXO1 IFNG LATS1 MDM2
18 limbs/digits/tail MP:0005371 9.95 EGFR FOXO1 MDM2 TNF TP53 VEGFA
19 normal MP:0002873 9.76 EGFR FOXO1 IFNG LATS1 MDM2 MKI67
20 renal/urinary system MP:0005367 9.5 BCL2 CSF3 EGFR IFNG MDM2 TP53
21 reproductive system MP:0005389 9.32 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 602)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lopinavir Approved Phase 4 192725-17-0 92727
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Fosaprepitant Approved Phase 4 172673-20-0 219090
5
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
6
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
7
Dalteparin Approved Phase 4 9005-49-6
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Enoxaparin Approved Phase 4 9005-49-6 772
10 Cytochrome P-450 CYP3A Inhibitors Phase 4
11 neurokinin A Phase 4
12
Substance P Phase 4 33507-63-0 44359816
13 Neurokinin-1 Receptor Antagonists Phase 4
14 Fibrinolytic Agents Phase 4
15 Anticoagulants Phase 4
16 calcium heparin Phase 4
17 Heparin, Low-Molecular-Weight Phase 4
18 Platelet Aggregation Inhibitors Phase 4
19 Antipyretics Phase 4
20
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
21
Morphine Approved, Investigational Phase 3 57-27-2 5288826
22
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
23
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
24
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
27
Nicotine Approved Phase 3 54-11-5 942 89594
28
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
29
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
30
Sulfamethoxazole Approved Phase 3 723-46-6 5329
31
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
32
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
33
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
34
Varenicline Approved, Investigational Phase 3 249296-44-4 5310966
35
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
36
Epirubicin Approved Phase 3 56420-45-2 41867
37
Ceritinib Approved Phase 3 1032900-25-6
38
Palbociclib Approved, Investigational Phase 3 571190-30-2 11431660 5005498 5330286
39 Cranberry Approved, Investigational Phase 3
40 Grape Approved Phase 3
41
Denosumab Approved Phase 3 615258-40-7
42
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
43
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
44
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
45
Daunorubicin Approved Phase 3 20830-81-3 30323
46
Idarubicin Approved Phase 3 58957-92-9 42890
47
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
48
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
49
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
50
Cetuximab Approved Phase 3 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 1716)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
4 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
5 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
6 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
7 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
8 An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
9 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
10 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
11 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
12 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Not yet recruiting NCT04033081 Phase 4
13 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
14 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
15 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
16 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
17 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
18 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
19 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
21 Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
22 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
23 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
24 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Unknown status NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
25 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
26 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
27 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
28 Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases Unknown status NCT01842048 Phase 3
29 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
30 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
31 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
32 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
33 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
34 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
35 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
36 A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma. Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
37 A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
38 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
39 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
40 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
41 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
42 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
43 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
44 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
45 A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies. Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
46 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
47 Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
48 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
49 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
50 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

# Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 29

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

40
Bone, Lung, Breast, T Cells, Uterus, Brain, Skin

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 7605)
# Title Authors PMID Year
1
CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study. 42
31509443 2019
2
Successful application of modified keystone flaps following skin tumor ablation. 42
31577777 2019
3
Secondary chondrosarcoma arising from osteochondroma: outcomes and prognostic factors. 42
31564158 2019
4
Radiomics and Machine Learning With Multiparametric Preoperative MRI May Accurately Predict the Histopathological Grades of Soft Tissue Sarcomas. 61
31486565 2020
5
Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma. 61
31592798 2020
6
Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. 61
31814291 2020
7
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. 61
31896519 2020
8
IMRiS phase II study of IMRT in limb sarcomas: Results of the pre-trial QA facility questionnaire and workshop. 61
31902458 2020
9
Experiences of return to work after treatment for extremital soft tissue or bone sarcoma: Between distraction and leaving the disease behind. 61
32017298 2020
10
Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: A systematic review and meta-analysis. 61
32022262 2020
11
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. 61
31696433 2020
12
Restoration of microRNA-197 expression suppresses oncogenicity in fibrosarcoma through negative regulation of RAN. 61
32027089 2020
13
Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. 61
31750944 2020
14
A Rare Case of Primary Dermal Clear Cell Sarcoma with Focal Epidermotropism: An Entity Difficult to Distinguish from Melanoma. 61
32012324 2020
15
Primary desmoplastic small round cell tumor of the tibia: PET/CT and MRI presentation of a rare case and review of the literature. 61
31871884 2020
16
Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846. 61
31786466 2020
17
The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients. 61
31628508 2020
18
Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. 61
31839218 2020
19
Extremity Soft Tissue Sarcoma: Role of Local Control. 61
32025823 2020
20
Prognoses of superficial soft tissue sarcoma: The importance of fascia-tumor relationship on MRI. 61
31610904 2020
21
Undifferentiated small round cell sarcoma in a young male: a case report. 61
32014859 2020
22
Stereotactic Body Radiotherapy Versus Metastasectomy in Patients With Pulmonary Metastases From Soft Tissue Sarcoma. 61
32024603 2020
23
Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index. 61
31630234 2020
24
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. 61
32020530 2020
25
The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. 61
31594823 2020
26
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. 61
31821732 2020
27
Primary cutaneous alveolar rhabdomyosarcoma in an adolescent - A challenging diagnosis. 61
31797424 2020
28
Comparison between Fluorescence in-situ Hybridization (FISH), Reverse Transcriptase PCR (RT-PCR) and fragment analysis, for detection of t (X; 18) (p11; q11) translocation in synovial sarcomas. 61
32031125 2020
29
Sports activity after soft tissue sarcoma of the lower extremity. 61
30620226 2020
30
Parapharyngeal Alveolar Soft Part Sarcoma in a 5-Year-Old Child. 61
31821212 2020
31
Alveolar soft part sarcoma of the right calf: A case report. 61
32000418 2020
32
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors. 61
31969978 2020
33
Simultaneous Left Ventricular Volume and Strain Changes During Chemotherapy Associate With 2-Year Postchemotherapy Measures of Left Ventricular Ejection Fraction. 61
31959033 2020
34
Semiparametric modelling and estimation of covariate-adjusted dependence between bivariate recurrent events. 61
31994170 2020
35
Validation process of Toronto Exremity Salvage Score in Italian: A quality of life measure for patients with extremity bone and soft tissue tumors. 61
31957034 2020
36
Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. 61
31898195 2020
37
Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. 61
31494391 2020
38
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report. 61
31924259 2020
39
Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion. 61
31672672 2020
40
Immediate Versus Staged Soft Tissue Reconstruction After Soft Tissue Sarcoma Resection Has Similar Wound and Oncologic Outcomes. 61
31913884 2020
41
Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: A report from the St. Jude Lifetime Cohort. 61
31913509 2020
42
Giant Malignant Peripheral Nerve Sheath Tumor of the Head and Neck: A Case Report and Literature Review. 61
31914814 2020
43
Urgent Proton Beam Therapy With Interinstitutional Transfer for Patients With Intracranial Rhabdomyosarcoma: Report of 3 Cases. 61
31688631 2020
44
Experience with eribulin in pretreated patients with advanced liposarcoma: a case series. 61
31858818 2020
45
Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi-centre study. 61
32003475 2020
46
Patterns of Radiotherapy Use and Outcomes in Head and Neck Soft-Tissue Sarcoma in a National Cohort. 61
30892716 2020
47
Comparison of CT and MRI images for the prediction of soft-tissue sarcoma grading and lung metastasis via a convolutional neural networks model. 61
31575409 2020
48
Efficacy and safety of CT-guided 125I seed implantation as a salvage treatment for locally recurrent head and neck soft tissue sarcoma after surgery and external beam radiotherapy: A 12-year study at a single institution. 61
31653566 2020
49
Giant variant of acquired perforating dermatosis, clinically masquerading as a sarcoma: A report of a rare case. 61
32031142 2020
50
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response. 61
31994460 2020

Variations for Soft Tissue Sarcoma

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 VEGFA TP53 TNF MDM2 IFNG FOXO1
2
Show member pathways
13.75 VEGFA TP53 TNF MDM2 FOXO1 EGFR
3
Show member pathways
13.35 TP53 TNF MDM2 FOXO1 EGFR CSF3
4
Show member pathways
13.24 VEGFA TP53 TNF IFNG FOXO1 EGFR
5
Show member pathways
13.15 TP53 TNF IFNG FOXO1 EGFR BCL2
6
Show member pathways
12.9 VEGFA TP53 TNF EGFR BCL2
7
Show member pathways
12.88 VEGFA TP53 TNF MDM2 EGFR BCL2
8
Show member pathways
12.78 TP53 TNF MDM2 IFNG BCL2
9
Show member pathways
12.77 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
10 12.64 VEGFA TP53 MDM2 IFNG FOXO1 EGFR
11
Show member pathways
12.62 TP53 MDM2 FOXO1 EGFR BCL2
12
Show member pathways
12.61 TP53 TNF IFNG EGFR
13
Show member pathways
12.59 VEGFA TP53 TNF MDM2 FOXO1 EGFR
14
Show member pathways
12.51 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
15 12.47 TP53 MKI67 MDM2 LATS1
16
Show member pathways
12.47 TP53 TNF IFNG FOXO1 EGFR BCL2
17
Show member pathways
12.41 TP53 MDM2 EGFR BCL2
18 12.37 VEGFA TP53 MDM2 EGFR BCL2 ABCB1
19
Show member pathways
12.3 IFNG EGFR CSF3 BCL2
20 12.23 TP53 MDM2 FOXO1 EWSR1
21
Show member pathways
12.22 TP53 TNF IFNG EGFR
22 12.22 VEGFA TP53 TNF MDM2 EGFR
23
Show member pathways
12.18 TP53 MDM2 FOXO1 EGFR BCL2
24 12.11 VEGFA TP53 TNF IFNG EGFR
25 12.11 TP53 TNF MDM2 FOXO1 EGFR BCL2
26
Show member pathways
12.04 MDM2 FOXO1 EGFR
27 12.04 TP53 MDM2 EGFR BCL2
28 11.99 TP53 TNF IFNG EGFR
29 11.97 TP53 MDM2 FOXO1
30 11.97 TP53 TNF BCL2
31 11.97 VEGFA TP53 TNF IFNG BCL2
32 11.96 TNF IFNG CSF3
33 11.95 TP53 MDM2 BCL2
34
Show member pathways
11.94 TP53 TNF BCL2
35 11.94 TP53 MDM2 FOXO1 EGFR
36 11.92 VEGFA IFNG EGFR BCL2
37 11.9 TP53 MDM2 IFNG BCL2
38 11.86 VEGFA TNF FOXO1 BCL2
39 11.84 VEGFA TNF IFNG
40 11.83 MDM2 FOXO1 EGFR
41 11.78 TP53 MDM2 IFNG
42 11.78 VEGFA TP53 TNF FOXO1 BCL2
43 11.72 TP53 MDM2 BCL2
44 11.7 VEGFA TP53 MDM2 EGFR
45 11.67 VEGFA TP53 MDM2 BCL2
46
Show member pathways
11.65 VEGFA TNF IFNG
47 11.62 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
48 11.58 VEGFA TP53 MDM2
49 11.57 TP53 MDM2 FOXO1
50 11.54 TNF IFNG CSF3

GO Terms for Soft Tissue Sarcoma

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 VEGFA TP53 TNF FOXO1 EGFR CSF3
2 regulation of transcription by RNA polymerase II GO:0006357 10.09 VEGFA TP53 TNF FOXO1 EGFR
3 negative regulation of transcription, DNA-templated GO:0045892 10.03 TP53 TNF MDM2 IFNG FOXO1
4 negative regulation of transcription by RNA polymerase II GO:0000122 10.01 VEGFA TP53 TNF MDM2 IFNG FOXO1
5 positive regulation of apoptotic process GO:0043065 9.98 TP53 TNF LATS1 FOXO1
6 response to drug GO:0042493 9.96 TP53 MDM2 BCL2 ABCB1
7 positive regulation of gene expression GO:0010628 9.96 VEGFA TP53 TNF MDM2 IFNG
8 cell proliferation GO:0008283 9.91 TP53 MKI67 EGFR BCL2
9 regulation of cell proliferation GO:0042127 9.88 TP53 TNF FOXO1 EGFR
10 response to oxidative stress GO:0006979 9.87 TP53 EGFR BCL2
11 positive regulation of protein phosphorylation GO:0001934 9.85 VEGFA TNF IFNG EGFR
12 negative regulation of apoptotic process GO:0043066 9.85 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 VEGFA TP53 CSF3
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA TNF IFNG
15 negative regulation of gene expression GO:0010629 9.8 VEGFA TP53 TNF MDM2 IFNG
16 positive regulation of cell proliferation GO:0008284 9.8 VEGFA MDM2 IFNG EGFR CSF3 BCL2
17 positive regulation of MAP kinase activity GO:0043406 9.77 VEGFA TNF EGFR
18 humoral immune response GO:0006959 9.77 TNF IFNG BCL2
19 positive regulation of protein localization to plasma membrane GO:1903078 9.74 TNF IFNG EGFR
20 cellular response to hypoxia GO:0071456 9.73 VEGFA TP53 MDM2 BCL2
21 positive regulation of protein complex assembly GO:0031334 9.7 VEGFA TNF IFNG
22 positive regulation of amyloid-beta formation GO:1902004 9.69 TNF IFNG
23 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 TNF IFNG
24 digestive tract morphogenesis GO:0048546 9.68 EGFR BCL2
25 cardiac septum morphogenesis GO:0060411 9.68 TP53 MDM2
26 positive regulation of leukocyte migration GO:0002687 9.67 VEGFA TP53
27 regulation of mitochondrial membrane permeability GO:0046902 9.67 TP53 BCL2
28 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IFNG
29 response to UV-B GO:0010224 9.66 TP53 BCL2
30 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 EGFR
31 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNG
32 response to salt stress GO:0009651 9.64 TP53 TNF
33 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TP53 TNF FOXO1 CSF3 BCL2
34 cellular response to UV-C GO:0071494 9.62 TP53 MDM2
35 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.62 VEGFA TP53
36 T cell lineage commitment GO:0002360 9.61 TP53 BCL2
37 B cell lineage commitment GO:0002326 9.58 TP53 BCL2
38 cellular response to actinomycin D GO:0072717 9.51 TP53 MDM2
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 TNF IFNG
40 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
41 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
42 astrocyte activation GO:0048143 9.43 TNF IFNG EGFR
43 negative regulation of mitotic cell cycle GO:0045930 9.26 TP53 TNF EGFR BCL2
44 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.1 VEGFA TNF LATS1 EGFR CSF3 BCL2

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.71 TP53 MDM2 EGFR CSF3
2 cytokine activity GO:0005125 9.56 VEGFA TNF IFNG CSF3
3 protease binding GO:0002020 9.54 TP53 TNF BCL2
4 protein phosphatase binding GO:0019903 9.5 TP53 EGFR BCL2
5 identical protein binding GO:0042802 9.5 VEGFA TP53 TNF MDM2 EWSR1 EGFR
6 protein phosphatase 2A binding GO:0051721 9.33 TP53 FOXO1 BCL2
7 ubiquitin protein ligase binding GO:0031625 9.1 TP53 MDM2 FOXO1 EGFR BCL2 ABCB1

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....